Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when,...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsson, Sigrid, Leapman, Michael, Carroll, Peter, Schröder, Fritz, Albertsen, Peter C., Ilic, Dragan, Barry, Michael, Frosch, Dominick L., Vickers, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Forum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662021/
https://www.ncbi.nlm.nih.gov/pubmed/26612204
http://dx.doi.org/10.1186/s12916-015-0526-x
Descripción
Sumario:Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine’s ‘Spotlight on Prostate Cancer’ article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world’s key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts’ views and give their own personal opinions on PSA screening.

Ejemplares similares